Acadia Pharmaceuticals (ACAD) EBIAT (2010 - 2026)
Acadia Pharmaceuticals' quarterly EBIAT came in at $3.6 million in Q1 2026, down 80.84% year-on-year from $19.0 million in Q1 2025, and down 98.67% quarter-over-quarter from $273.6 million in Q4 2025.
Acadia Pharmaceuticals has reported EBIAT for 17 years, with the latest figure at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT fell 80.84% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $375.6 million (up 64.12% YoY), and the FY2025 full-year result was $391.0 million, up 72.66% from the prior year.
- EBIAT for Q1 2026 stood at $3.6 million, down from $273.6 million in the prior quarter.
- The five-year high for EBIAT was $273.6 million in Q4 2025, with the low at -$113.1 million in Q1 2022.
- Average EBIAT over 5 years is $20.2 million, with a median of $16.6 million recorded in 2024.
- Year-over-year, EBIAT tumbled 139.77% in 2023 and soared 2897.22% in 2024.
- Tracing ACAD's EBIAT over 5 years: stood at -$41.7 million in 2022, then soared by 209.76% to $45.8 million in 2023, then surged by 213.87% to $143.7 million in 2024, then soared by 90.32% to $273.6 million in 2025, then sank by 98.67% to $3.6 million in 2026.
- The last three EBIAT figures came in at $3.6 million (Q1 2026), $273.6 million (Q4 2025), and $71.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 3.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.64 Mn |
| Dec 31, 2025 | 273.57 Mn |
| Sep 30, 2025 | 71.78 Mn |
| Jun 30, 2025 | 26.67 Mn |
| Mar 31, 2025 | 18.99 Mn |
| Dec 31, 2024 | 143.74 Mn |
| Sep 30, 2024 | 32.77 Mn |
| Jun 30, 2024 | 33.39 Mn |
| Mar 31, 2024 | 16.56 Mn |
| Dec 31, 2023 | 45.80 Mn |
| Sep 30, 2023 | -65.18 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | -43.02 Mn |
| Dec 31, 2022 | -41.73 Mn |
| Sep 30, 2022 | -27.18 Mn |
| Jun 30, 2022 | -34.01 Mn |
| Mar 31, 2022 | -113.06 Mn |
| Dec 31, 2021 | -43.09 Mn |
| Sep 30, 2021 | -14.46 Mn |
| Jun 30, 2021 | -43.87 Mn |
| Mar 31, 2021 | -66.45 Mn |
| Dec 31, 2020 | -66.76 Mn |
| Sep 30, 2020 | -84.66 Mn |
| Jun 30, 2020 | -42.14 Mn |
| Mar 31, 2020 | -88.02 Mn |
| Dec 31, 2019 | -53.04 Mn |
| Sep 30, 2019 | -41.98 Mn |
| Jun 30, 2019 | -54.94 Mn |
| Mar 31, 2019 | -85.30 Mn |
| Dec 31, 2018 | -65.49 Mn |
| Sep 30, 2018 | -62.14 Mn |
| Jun 30, 2018 | -63.27 Mn |
| Mar 31, 2018 | -54.30 Mn |
| Dec 31, 2017 | -68.87 Mn |
| Sep 30, 2017 | -65.25 Mn |
| Jun 30, 2017 | -67.44 Mn |
| Mar 31, 2017 | -87.84 Mn |
| Dec 31, 2016 | -78.70 Mn |
| Sep 30, 2016 | -71.61 Mn |
| Jun 30, 2016 | -71.32 Mn |
| Mar 31, 2016 | -49.76 Mn |
| Dec 31, 2015 | -45.78 Mn |
| Sep 30, 2015 | -38.91 Mn |
| Jun 30, 2015 | -39.38 Mn |
| Mar 31, 2015 | -40.38 Mn |
| Dec 31, 2014 | -28.37 Mn |
| Sep 30, 2014 | -24.79 Mn |
| Jun 30, 2014 | -21.50 Mn |
| Mar 31, 2014 | -17.83 Mn |
| Dec 31, 2013 | -12.05 Mn |
| Sep 30, 2013 | -10.70 Mn |
| Jun 30, 2013 | -9.08 Mn |
| Mar 31, 2013 | -6.12 Mn |
| Dec 31, 2012 | -6.81 Mn |
| Sep 30, 2012 | -2.40 Mn |
| Jun 30, 2012 | -5.42 Mn |
| Mar 31, 2012 | -6.22 Mn |
| Dec 31, 2011 | -5.30 Mn |
| Sep 30, 2011 | -5.08 Mn |
| Jun 30, 2011 | -6.56 Mn |
| Mar 31, 2011 | -5.83 Mn |
| Dec 31, 2010 | 29.14 Mn |
| Sep 30, 2010 | -4.23 Mn |